Skip to main content

Security report for galafold.com

Amicus Therapeutics, Inc. · Healthcare · United States

Medium risk. 5 critical or high findings in SSL/TLS, GDPR outside view and 1 other check.

Security score

66/100

Risk levelMedium

0–100, higher is better. How it is calculated

Galafold.com is the official patient website for Galafold, an FDA-approved oral therapy for adults with Fabry disease. The site is operated by Amicus Therapeutics, Inc., a medium-sized healthcare company based in the United States. The website provides comprehensive patient education, treatment information, support programs, and resources tailored to patients and healthcare professionals. It maintains a strong market position in the niche pharmaceutical sector focused on rare diseases. Technically, the site employs modern web technologies including Bootstrap, jQuery, and various analytics and marketing tools, ensuring good performance, mobile optimization, and accessibility compliance. Security posture is solid with HTTPS, privacy policies, cookie consent, and data protection officer contact information, though improvements could be made by enabling DNSSEC and security headers. Overall, the website is professional, trustworthy, and compliant with relevant regulations, supporting patient engagement and education effectively.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

Need hands-on remediation? Email guard@offseq.com

Keep watching galafold.com

This scan found 25 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
25
Email security
70
DNS health
75
Network security
100
GDPR outside view
53
Average
66

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Amicus Therapeutics leverages Galafold.com to engage directly with patients affected by Fabry disease, providing educational content, patient stories, and support services including financial assistance. The business model centers on pharmaceutical product promotion and patient support, with a clear segmentation between patients and healthcare professionals via separate domains. The company demonstrates a mature digital presence with integrated marketing and analytics tools, indicating a strategic approach to patient outreach and brand positioning. Partnerships with related domains such as amicusrx.com and galafoldhcp.com reinforce the ecosystem supporting both patients and healthcare providers. The site’s content quality and trust signals such as FDA approval and registered trademarks enhance credibility and market differentiation.

Security posture

The website exhibits a good security posture with enforced HTTPS, use of reCAPTCHA to protect forms, and a cookie consent mechanism aligned with privacy regulations. The presence of a named Data Protection Officer and clear privacy policies indicate compliance with GDPR and US privacy standards. However, the absence of DNSSEC and security headers like Content Security Policy or HSTS suggests room for improvement. No vulnerabilities or exposed sensitive data were detected in the HTML content. The site uses multiple third-party scripts for analytics and marketing, which should be regularly audited to mitigate supply chain risks. Incident response and vulnerability disclosure information are not publicly available, representing a potential compliance gap.

Recommendations

  1. Enable DNSSEC on the domain to enhance DNS security and prevent spoofing.
  2. Implement standard security headers such as Content Security Policy, HSTS, X-Frame-Options, and X-Content-Type-Options.
  3. Publish a dedicated security policy and vulnerability disclosure page to improve transparency and compliance.
  4. Provide public incident response contact information to facilitate timely reporting and handling of security issues.
  5. Regularly review and update third-party scripts and dependencies to minimize risk from vulnerable libraries.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Amicus Therapeutics, Inc.
Description
Official patient site for Galafold, an FDA-approved oral therapy for adults with Fabry disease and an amenable GLA variant. Provides treatment information, patient stories, support programs, and educational resources.
Key services
Patient education, Treatment information, Support programs including financial assistance, Healthcare professional resources (via separate site)
Content quality
excellent
Branding
consistent

Technology

Stack
Bootstrap 4.3.1, jQuery 3.7.1, Slick Carousel, Google Fonts, Google Tag Manager, Google Analytics, Facebook Pixel, Twitter Universal Website Tag, Bing UET, Mouseflow, Vimeo Player API, OneTrust Cookie Consent, Accessibe Accessibility Plugin, reCAPTCHA
Frameworks
Bootstrap
Performance
moderate
Mobile
excellent
Accessibility
excellent
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Use of reCAPTCHA
  • Cookie consent mechanism
  • Privacy policy and data protection officer contact
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Analytics, Mouseflow
Tracking level
moderate
Privacy practices
good

Advertising

Ad networks
Facebook Ads, Twitter Ads, Bing Ads, Google Ads
Tracking pixels
Facebook Pixel, Mouseflow, Bing UET, Twitter Universal Website Tag
Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured for patient education.
  2. Strong focus on compliance with US regulations and patient safety.
  3. Multiple accessibility and privacy features implemented.
  4. Use of multiple third-party analytics and marketing tools.
  5. No signs of malicious or suspicious content.
  6. WHOIS data supports legitimacy and business continuity.
Technical notes

Notes

The website is built on a modern technology stack featuring Bootstrap 4.3.1 for responsive design, jQuery for DOM manipulation, and slick-carousel for interactive elements. It integrates multiple analytics and marketing tools including Google Analytics, Google Tag Manager, Facebook Pixel, Twitter Tag, Bing UET, and Mouseflow for user behavior tracking. Accessibility is enhanced via the Accessibe plugin, and cookie compliance is managed through OneTrust. The site is hosted with GoDaddy.com, LLC as per WHOIS data. Performance is moderate with asynchronous loading of scripts and optimized fonts. The site is mobile-optimized and SEO-friendly with proper meta tags and structured navigation. No CMS is explicitly detected, suggesting a custom or static site architecture. Overall, the technical implementation supports a professional and user-friendly experience with opportunities to strengthen security configurations.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with galafold.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review galafold.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.